Related Experiment Video
Updated: Feb 21, 2026
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.8K
Molecular radiotheragnostics in prostate cancer
1Royal Marsden NHS Foundation Trust, London, UK yong.du@rmh.nhs.uk.
Clinical Medicine (London, England)
|October 5, 2017
Summary
Personalized prostate cancer management utilizes two radiotheranostic principles. These approaches target bone metastases and prostate-specific membrane antigen (PSMA) for improved patient outcomes in advanced disease.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmaceutical Therapy
Background:
- Prostate cancer management benefits from personalized approaches.
- Radiopharmaceuticals offer targeted therapy for bone metastases and PSMA-positive tumors.
Purpose of the Study:
- To outline two distinct molecular radiotheranostic principles for prostate cancer.
- To highlight their application in personalized patient management.
Main Methods:
- Utilizing gamma or positron emitters for identifying osteoblastic metastases for subsequent beta or alpha therapy.
- Employing prostate-specific membrane antigen (PSMA) targeted agents labeled with positron or gamma emitters for imaging, followed by beta or alpha emitters for treatment.
Main Results:
- Bone-seeking beta-emitting radiopharmaceuticals provide palliation for bone metastases.
- Radium-223 dichloride (alpha emitter) improves survival in castration-resistant prostate cancer with bone metastases.
- PSMA-targeted theranostics (e.g., 68Ga for imaging, 177Lu or 225Ac for therapy) offer a dual approach.
Conclusions:
- Molecular radiotheranostics provide personalized treatment strategies in prostate cancer.
- Targeting bone metastases and PSMA are key principles in advanced prostate cancer therapy.
- Theranostic approaches with alpha and beta emitters show significant clinical benefit.
